| Typicality: | 0.397 |
| Saliency: | 0.474 |
| to existing drugs | 12 | other |
| rapidly | 7 | manner |
| to ibalizumab | 4 | transitive-object |
| hiv → develop → resistance | 24 |
| hiv → evolve → resistance | 6 |
| negative | neutral | positive |
| 0.515 | 0.452 | 0.033 |
| Raw frequency | 30 |
| Normalized frequency | 0.474 |
| Modifier score | 0.600 |
| Perplexity | 239.314 |